Gloria Ying (06821) plans to invest 300 million yuan to establish a biomedical innovation and synthetic biology industry investment fund with Haihe Fund, Eco-City State-owned Assets, etc.

Gloria Ying (06821) announced that in order to seize the booming development opportunities in the domestic and foreign innovative drug markets, by investing in specialized students...

Zhitong Finance07:38

A subsidiary of Gloria Incorporated (06821.HK) and CNBC Hengze jointly set up a fund

Gelonghui, April 30, 丨 Gloria Ying (06821.HK) announced that on April 29, 2024, Gloria Life Science Technology (a wholly-owned subsidiary of the company, as limited partner) signed a partnership agreement with CITIC Hengze (as general partner), Haizunchuang Enterprise Management (as general partner), Haihe Industrial Fund (as limited partner) and Tianjin Eco-City (as limited partner) to jointly establish a fund to invest in innovative biopharmaceuticals, synthetic biology and other industries in the future. According to the partnership agreement, the total amount of capital pledged by the fund is RMB 754 million, of which (i) CNBC Hengze will

Gelonghui Finance07:32

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

It's been a good week for Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) shareholders, because the company has just released its latest first-quarter results, and the shares gained 5.7% to CN

Simply Wall StApr 28 08:43

Gloria Ying (002821): Small molecule business continues to grow and accelerate overseas layout

Core idea: Promote the development of small-molecule CDMO and promote the rebalance of the company's overall profitability. According to the company's quarterly report, the company achieved total revenue of 1,400 billion yuan, a year-on-year decrease of 37.76%, excluding large orders for the same period last year

廣發證券Apr 28 00:00

Gloria Ying (002821): Regular business is growing steadily, and emerging businesses continue to advance

Guide to this report: After excluding large orders, regular business grew steadily, and emerging businesses such as peptides continued to advance, optimistic about long-term growth space, and maintained an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. 2024Q1 revenue of 1.400 billion yuan (-37

國泰君安Apr 27 00:00

Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy

04:44 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy Price (RMB): ¥80.99, Change: ¥+4.13, Percent Change: +5.37%

MT NewswiresApr 26 16:44